BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31396919)

  • 1. Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.
    Di Minno MND; Ambrosino P; Buonomo AR; Pinchera B; Calcaterra I; Crispo M; Scotto R; Borgia F; Mattia C; Gentile I
    Intern Emerg Med; 2020 Mar; 15(2):263-271. PubMed ID: 31396919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes.
    Sasso FC; Pafundi PC; Caturano A; Galiero R; Vetrano E; Nevola R; Petta S; Fracanzani AL; Coppola C; Di Marco V; Solano A; Lombardi R; Giordano M; Craxi A; Perrella A; Sardu C; Marfella R; Salvatore T; Adinolfi LE; Rinaldi L
    Nutr Metab Cardiovasc Dis; 2021 Jul; 31(8):2345-2353. PubMed ID: 34053830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
    Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
    Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
    Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
    Abd Alla MDA; El Awady MK; Dawood RM; Elhawary MA; Al-Azhari SS; Galal AGM
    Arch Virol; 2018 Oct; 163(10):2765-2774. PubMed ID: 29971486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
    Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
    J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis.
    Villani R; Monami M; Di Cosimo F; Fioravanti G; Mannucci E; Vendemiale G; Serviddio G
    J Viral Hepat; 2019 Nov; 26(11):1249-1256. PubMed ID: 31243849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Adinolfi LE; Petta S; Fracanzani AL; Coppola C; Narciso V; Nevola R; Rinaldi L; Calvaruso V; Staiano L; Di Marco V; Marrone A; Pafundi PC; Solano A; Lombardi R; Sasso FC; Saturnino M; Rini F; Guerrera B; Troina G; Giordano M; Craxì A
    Atherosclerosis; 2020 Mar; 296():40-47. PubMed ID: 32005004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
    Lin M; Kramer J; White D; Cao Y; Tavakoli-Tabasi S; Madu S; Smith D; Asch SM; El-Serag HB; Kanwal F
    Aliment Pharmacol Ther; 2017 Nov; 46(10):992-1000. PubMed ID: 28949020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Sagnelli E; Stroffolini T; Sagnelli C; Cacopardo B; Andriulli A; Babudieri S; Coppola N; Gaeta GB; Almasio PL
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):676-681. PubMed ID: 29465473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
    Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study.
    Ibáñez-Samaniego L; Rapado-Castro M; Cabrero L; Navarrete C; García-Mulas S; Ahumada A; Marquez L; Pérez MD; Rincon D; Bañares R; Garcia-Martinez R
    Eur J Neurol; 2022 Feb; 29(2):400-412. PubMed ID: 34634159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function.
    Schmidt FP; Zimmermann T; Wenz T; Schnorbus B; Ostad MA; Feist C; Grambihler A; Schattenberg JM; Sprinzl MF; Münzel T; Galle PR
    Int J Cardiol; 2018 Nov; 271():296-300. PubMed ID: 30077529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.